CA-XSOLLA
Xsolla, a global video game commerce company, proudly extends its strategic partnership with GameAnalytics, the leading analytics service for game developers and publishers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240822075172/en/
(Graphic: Xsolla)
The partnership marks a significant expansion of Xsolla's capabilities. By integrating GameAnalytics directly into the Xsolla Backend Solution, developers can access powerful analytics and monetization tools in one seamless interface. This integration redefines how developers approach game analytics and monetization, providing a comprehensive toolkit to enhance their understanding of player behavior, optimize revenue streams, and drive better business outcomes. Developers can now track critical metrics such as conversion rates, player retention, and lifetime value while leveraging Xsolla’s extensive payment processing capabilities, offering a unique advantage by combining data-driven insights and robust monetization tools under a single umbrella.
Jean-Philippe Steinmetz, Head of Xsolla Backend, highlights the strategic importance of expanding the partnership: “By incorporating GameAnalytics into Xsolla Backend, we are enhancing our platform's ability to deliver comprehensive game analytics and benchmarking. This collaboration allows us to provide developers with a deeper understanding of their games' performance, enabling them to make informed decisions that drive success.”
GameAnalytics, known for serving over 12,000 game studios and offering insights on more than 2.3 billion players each month, brings unparalleled expertise in analytics to this partnership. The integration with Xsolla Backend allows developers to access these insights effortlessly, providing a clear view of how their games perform across various metrics. This partnership enhances the analytic capabilities available to developers and simplifies integrating these insights with monetization strategies, ultimately helping developers maximize their revenue potential.
Allison Bilas, COO at GameAnalytics, expressed her enthusiasm for the expansion of the partnership: “We are excited to expand our relationship with Xsolla by integrating our analytics suite into Xsolla Backend. This integration allows us to deliver even more value to developers, helping them better understand their games and make data-driven decisions to enhance player experiences.”
The collaboration underscores Xsolla’s dedication to providing game developers with the tools they need to succeed in a competitive market. By combining the power and efficiency of Xsolla Backend with Xsolla's payment and monetization tools and GameAnalytics' industry-leading data analysis capabilities, developers now have access to a powerful, all-in-one solution that simplifies the process of building, tracking, and improving game performance.
For more information, please visit xsolla.pro/xbegameanalytics.
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit xsolla.com
About GameAnalytics
GameAnalytics is the leading analytics solution for developers, game studios, and powerhouse publishers globally. Their network covers 100,000 games played by over 1.75 billion people for an average of 24 billion monthly sessions. The GameAnalytics platform enables game development teams to rapidly refine gameplay, improve retention, and increase revenue with real-time data analysis for all major game engines and operating systems through a simple SDK integration. GameAnalytics was founded in 2012 by Danish serial entrepreneur Morten E. Wulff, who remains the company's Chairman today. After raising over $8M in funding, the leading mobile advertising company, Mobvista, acquired the company in 2016. To learn more and get started for free, visit gameanalytics.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240822075172/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer lancerer Capego Practice Management – en cloud-løsning til moderne revisions- og bogføringsfirmaer1.9.2025 01:00:00 CEST | Pressemeddelelse
Dette cloudbaserede softwaresystem samler alt, hvad revisions- og bogføringsfirmaer har brug for, i én kraftfuld, forbundet platform, der er fuldt integreret med Capego-produktserien Wolters Kluwer Tax & Accounting Danmark er stolte af at kunne annoncere lanceringen af Capego Practice Management, en cloud-baseret løsning designet til at give revisions- og bogføringsfirmaer smartere og mere integrerede arbejdsgange. Capego-pakken samler nu alt, hvad firmaer har brug for – fra kundedata og opgavestyring til fakturering og compliance – i ét sikkert, skalerbart system. "Capego Practice Management repræsenterer et stort fremskridt i måden, hvorpå revisions- og bogføringsfirmaer kan operere i dagens digitale verden," siger Stefan Wahle, vicepræsident og general manager, Wolters Kluwer Tax & Accounting, Europa Region Nord. "Ved at samle kundesamarbejde, opgavestyring, compliance og fakturering i én fuldt integreret platform hjælper vi firmaer med at arbejde smartere, overholde reglerne og lev
Wolters Kluwer Launches Capego Practice Management - A Cloud Solution for Modern Tax and Accounting Firms1.9.2025 01:00:00 CEST | Press release
This cloud-based software system brings together everything tax and accounting firms need into one powerful, connected platform that’s fully integrated with the Capego suite of products Wolters Kluwer Tax & Accounting Denmark is proud to announce the launch of Capego Practice Management, a cloud-native solution designed to empower tax and accounting firms with smarter, more connected workflows. The Capego suite now brings together everything firms need—from client data and task management to invoicing and compliance—into one secure, scalable system. “Capego Practice Management represents a major leap forward in how tax and accounting firms can operate in today’s digital-first world,” said Stefan Wahle, Vice President & General Manager, Wolters Kluwer Tax & Accounting, Europe Region North. “By bringing together client collaboration, task management, compliance, and invoicing into one fully integrated platform, we’re helping firms work smarter, stay compliant, and deliver exceptional ser
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release
− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card
WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release
DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i
Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release
Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom